Pediatric rheumatology

Early intensification versus step-up biologic strategies in systemic juvenile idiopathic arthritis: a Bayesian network meta-analysis of remission and safety outcomes

Pediatr Rheumatol Online JPublished Systematic review and Bayesian network meta-analysis

Authors' conclusion

In sJIA, immediate intensive IL-1/IL-6 therapy at diagnosis is more effective than a step-up approach in achieving and maintaining CID/remission, while also having an acceptable safety profile, supporting the initial "target-to-treat (T2T)" strategy.

Study context

Population
Patients with Systemic Juvenile Idiopathic Arthritis (sJIA); databases searched from inception to October 2025
Participants
1,548 patients15 studies
Comparison
Early IL-1/IL-6 blockade vs step-up biologic strategies, anakinra, canakinumab, tocilizumab, conventional care and mixed biologic strategies
Outcome
CID/remission rate
Methodological detailsRandomized controlled trials (RCTs), prospective cohorts and retrospective/registry studies, random-effects and Bayesian hierarchical network models, PRISMA 2020 and PRISMA-NMA, ROB-2, NOS and GRADE
  • RCTs, prospective cohorts and retrospective/registry studies
  • Random-effects and Bayesian hierarchical network models
  • PRISMA 2020 and PRISMA-NMA
  • ROB-2, NOS and GRADE

Pooled result

As reported in the abstract

CID/remission · during follow-up
  • Approximately two-thirds of patients achieved CID/remission during follow-up (pooled, random-effects model)
  • Early IL-1/IL-6 strategy had a more favorable response rate (stratification)
  • SUCRA ranking: early IL-1/IL-6 blockade first, followed by anakinra and canakinumab; tocilizumab in the middle; conventional care and mixed biologic strategies last

Safety

Adverse events (AEs) (normalized per patient-year)

Overall AE rate low and consistent across studies; IL-1/IL-6 targeted drugs had a favorable safety profile

Original publication

Early intensification versus step-up biologic strategies in systemic juvenile idiopathic arthritis: a Bayesian network meta-analysis of remission and safety outcomes. Pediatr Rheumatol Online J. Published 25 May 2026. doi:10.1186/s12969-026-01221-8

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.